The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

Pad Chivukula Biography and Net Worth

COO of Arcturus Therapeutics

Dr. Pad Chivukula is the Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology. Prior to Arcturus, from 2008 until February 2013, Dr. Chivukula was employed by Nitto, where his titles included Group Leader and Chief Scientist. Dr. Chivukula brings over 15 years of experience in drug delivery and therapeutic drug development, including leading the polymeric RNAi research department at Nitto. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in nanoparticle technology.

What is Pad Chivukula's net worth?: The estimated net worth of Pad Chivukula is at least $12.39 million as of March 25th, 2024. Dr. Chivukula owns 473,448 shares of Arcturus Therapeutics stock worth more than $12,390,134 as of April 26th. This net worth approximation does not reflect any other assets that Dr. Chivukula may own. Additionally, Dr. Chivukula receives an annual salary of $787,500.00 as COO at Arcturus Therapeutics. Learn More about Pad Chivukula's net worth.
How old is Pad Chivukula?: Dr. Chivukula is currently 45 years old. There are 3 older executives and no younger executives at Arcturus Therapeutics. The oldest executive at Arcturus Therapeutics is Dr. Juergen Froehlich FCPh, M.D., MBA, Chief Medical Officer, who is 68 years old. Learn More on Pad Chivukula's age.
What is Pad Chivukula's salary?: As the COO of Arcturus Therapeutics Holdings Inc., Dr. Chivukula earns $787,500.00 per year. There are 2 executives that earn more than Dr. Chivukula. The highest earning executive at Arcturus Therapeutics is Mr. Joseph E. Payne M.Sc., Founder, President, CEO & Director, who commands a salary of $1,130,000.00 per year. Learn More on Pad Chivukula's salary.
How do I contact Pad Chivukula?: The corporate mailing address for Dr. Chivukula and other Arcturus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. Arcturus Therapeutics can also be reached via phone at (858) 900-2660 and via email at [email protected]. Learn More on Pad Chivukula's contact information.
Has Pad Chivukula been buying or selling shares of Arcturus Therapeutics?: Pad Chivukula has not been actively trading shares of Arcturus Therapeutics during the past quarter. Most recently, Pad Chivukula sold 17,435 shares of the business's stock in a transaction on Monday, March 25th. The shares were sold at an average price of $35.02, for a transaction totalling $610,573.70. Following the completion of the sale, the chief operating officer now directly owns 473,448 shares of the company's stock, valued at $16,580,148.96. Learn More on Pad Chivukula's trading history.
Are insiders buying or selling shares of Arcturus Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 10 times. They sold a total of 100,043 shares worth more than $3,194,114.35. The most recent insider tranaction occured on March, 25th when COO Pad Chivukula sold 17,435 shares worth more than $610,573.70. Insiders at Arcturus Therapeutics own 13.8% of the company. Learn More about insider trades at Arcturus Therapeutics.
Information on this page was last updated on 3/25/2024.

Pad Chivukula Insider Trading History at Arcturus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/25/2024	Sell	17,435	$35.02	$610,573.70	473,448
3/19/2024	Sell	8,565	$35.01	$299,860.65	490,883
11/1/2023	Sell	5,000	$18.72	$93,600.00	499,448
10/2/2023	Sell	5,000	$25.61	$128,050.00	504,448
9/1/2023	Sell	5,000	$31.45	$157,250.00	509,448
7/14/2023	Sell	25,000	$35.01	$875,250.00	519,448
7/3/2023	Sell	5,000	$28.75	$143,750.00	544,448
5/10/2023	Sell	17,075	$30.00	$512,250.00	562,373
5/1/2023	Sell	5,000	$25.93	$129,650.00	579,448
4/3/2023	Sell	5,000	$25.38	$126,900.00	584,448
3/6/2023	Sell	5,000	$16.07	$80,350.00	589,448
1/4/2022	Sell	8,100	$40.00	$324,000.00
12/16/2021	Sell	3,633	$40.00	$145,320.00
12/8/2021	Sell	6,367	$40.00	$254,680.00
11/1/2021	Sell	10,000	$44.41	$444,100.00
10/1/2021	Sell	10,000	$44.36	$443,600.00
9/1/2021	Sell	10,000	$55.86	$558,600.00
8/3/2021	Sell	10,000	$40.07	$400,700.00
1/4/2021	Sell	10,000	$46.40	$464,000.00
11/2/2020	Sell	10,000	$55.28	$552,800.00
10/1/2020	Sell	10,000	$42.83	$428,300.00
9/3/2020	Sell	10,000	$45.16	$451,600.00

Pad Chivukula Buying and Selling Activity at Arcturus Therapeutics

Arcturus Therapeutics Company Overview

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Today's Range

Now: $26.50

$25.84

$26.80

50 Day Range

MA: $33.94

$25.98

$42.99

2 Week Range

Now: $26.50

$17.52

$43.81

Volume

65,416 shs

Average Volume

449,757 shs

Market Capitalization

$713.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.6

The A.I. story nobody is telling you (Read ASAP)

From TradeSmith | Ad